Christina Anderson, MD
Dermatology · Saint Cloud, MNNPI 1053313692
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Bristol Myers Squibb at 30.6% of the total. Reporting peaked in 2019 at $221 and has fallen 91.1% since, to $20 in 2025.
Across 9 payments — averaging $51.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$142
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$121
- Incyte Corporation$101
- UCB, Inc.$46
- Novartis$34
- Viiv Healthcare Company$20
What the payments were for
- Food & beverage$464100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 2 | $142 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $121 |
| Incyte Corporation | 2 | $101 |
| UCB, Inc. | 1 | $46 |
| Novartis | 1 | $34 |
| Viiv Healthcare Company | 1 | $20 |
How this compares
$464 in reported general payments places this provider in the 65th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 31 | $212,744 |
| OtezlaApremilast | 11 | $110,913 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $86,081 |
| Humira(Cf)Adalimumab | 11 | $73,908 |
| AdbryTralokinumab-Ldrm | 13 | $47,830 |
| Calcipotriene | 42 | $6,567 |
| Metronidazole | 80 | $3,989 |
| Ivermectin | 16 | $3,845 |
| Tretinoin | 38 | $2,647 |
| Dapsone | 21 | $2,117 |
| Doxycycline Hyclate | 102 | $1,900 |
| Azelaic Acid | 16 | $1,890 |
| Ketoconazole | 109 | $1,603 |
| Tacrolimus | 13 | $1,262 |
| Fluocinonide | 36 | $1,168 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Saint Cloud
- Kristina ShafferEagan$538K
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- Afsaneh AlaviRochester$71K
- Todd SeelhammerSaint Paul$63K
- Brittney SchultzMinneapolis$52K
- David PearsonMinneapolis$46K
- Phillip EckerWayzata$31K
- Noah GoldfarbMinneapolis$30K
- Saranya WylesRochester$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.